![]() |
|
| Systematic (IUPAC) name | |
|---|---|
| (–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide | |
| Identifiers | |
| CAS number | 112111-43-0 |
| ATC code | N06BA07 |
| PubChem | 9690109 |
| ChemSpider | 7962943 |
| Chemical data | |
| Formula | C 15H15NO2S |
| Mol. mass | 273.351 |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic, including CYP3A4 and other pathways |
| Half life | 12-15 hrs |
| Excretion | Urine (as metabolites) |
| Therapeutic considerations | |
| Pregnancy cat. | C |
| Legal status | Schedule IV (US) ℞ Prescription only |
| Routes | Oral |
Armodafinil (Nuvigil) is a stimulant-like drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007. [1] Armodafinil is the active (−)-(R)-enantiomer of the racemic drug modafinil (Provigil).
Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition abnormalities associated with schizophrenia, and excessive sleepiness, and fatigue in conditions such as Parkinson's disease, cancer,[2 ] and narcolepsy, which is a sleep disorder. Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil.
Nuvigil is available for prescription as of June 1, 2009. As of January 6th, 2010, it is being considered for the first FDA-approved medicinally-specific drug for combating jet-lag
|
|||||||||||
|
|